Structure-activity relationships between the Aconitum C20-diterpenoid alkaloid derivatives and the growth suppressive activities of Non-Hodgkin’s lymphoma Raji cells and human hematopoietic stem/progenitor cells
- 26 September 2009
- journal article
- research article
- Published by Springer Nature in Investigational New Drugs
- Vol. 29 (1) , 1-8
Abstract
The anti-tumor properties of novel derivatives prepared from Aconitum C20-diterpenoid alkaloid, which show the least toxicity among the Aconitum alkaloids, were investigated in the Non-Hodgkin’s lymphoma cell line Raji cells. Two novel Aconitum C20-diterpenoid alkaloid derivatives, 11-m-Trifluorometylbenzoyl (Mb)-pseudokobuisne and 11-Anisoyl (As)-pseudokobusine, showed significant suppressive effects and their 50% inhibitory concentrations were 2.2 μg/ml and 2.4 μg/ml against Raji cells, respectively. Both compounds have the same structure except for a functional group in the C-11 position. One of the active compounds, 11-Mb-pseudokobusine, clearly inhibited the phosphorylation of extracellular signal-regulated kinase, induced enhanced phosphoinositide 3 kinase phosphorylation and led to the subsequent accumulation of G1 and/or sub G1 phase in Raji cells. In addition, no significant suppressive effects on the growth of human CD34+ hematopoietic stem/progenitor cells (HSPC) were observed by 11-Mb-pseudokobusine which showed a strong suppressive activity on the growth of Raji cells, whereas 11-As-pseudokobusine also a showed significantly suppressive effect on the growth of HSPC. Therefore, the atisine type structure characteristic of C20-diterpenoid alkaloids plays a very important role in the pharmacological properties. In particular, the C-11 residues are an important component for the anti-tumor properties and for the lower toxicity to hematopoiesis.Keywords
This publication has 23 references indexed in Scilit:
- Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK InhibitionCancer Research, 2009
- Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low‐grade B‐cell non‐Hodgkin lymphoma patientsCancer, 2008
- Microtubule depolymerization and phosphorylation of c-Jun N-terminal kinase-1 and p38 were involved in gambogic acid induced cell cycle arrest and apoptosis in human breast carcinoma MCF-7 cellsLife Sciences, 2008
- Suppressive effects of novel derivatives prepared from Aconitum alkaloids on tumor growthInvestigational New Drugs, 2008
- Inhibition of MAPK Kinase Signaling Pathways Suppressed Renal Cell Carcinoma Growth and Angiogenesis In vivoCancer Research, 2008
- Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemiaEuropean Journal of Haematology, 2007
- Disruption of the intracellular Ca2+ homeostasis in the cardiac excitation–contraction coupling is a crucial mechanism of arrhythmic toxicity in aconitine-induced cardiomyocytesBiochemical and Biophysical Research Communications, 2007
- Increasing Chemotherapy Dose Density and Intensity: Phase I Trials in Non-Small Cell Lung Cancer and Non-Hodgkin's LymphomaThe Oncologist, 2005
- Anticancer drug targets: growth factors and growth factor signalingJournal of Clinical Investigation, 2000
- Rituximab Immunotherapy for Non-Hodgkin's LymphomaCancer Biotherapy and Radiopharmaceuticals, 1999